JP2013505287A - ペプチドクリアリング剤 - Google Patents

ペプチドクリアリング剤 Download PDF

Info

Publication number
JP2013505287A
JP2013505287A JP2012530331A JP2012530331A JP2013505287A JP 2013505287 A JP2013505287 A JP 2013505287A JP 2012530331 A JP2012530331 A JP 2012530331A JP 2012530331 A JP2012530331 A JP 2012530331A JP 2013505287 A JP2013505287 A JP 2013505287A
Authority
JP
Japan
Prior art keywords
peptide
enzyme
binding
peptides
peptide according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012530331A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013505287A5 (https=
Inventor
デイビス，ポール・ジエイムズ
スカウテン，ジエームス・アレクサンデル
Original Assignee
モロジック リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by モロジック リミテッド filed Critical モロジック リミテッド
Publication of JP2013505287A publication Critical patent/JP2013505287A/ja
Publication of JP2013505287A5 publication Critical patent/JP2013505287A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A61K47/665—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells the pre-targeting system, clearing therapy or rescue therapy involving biotin-(strept) avidin systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Nanotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
JP2012530331A 2009-09-23 2010-09-23 ペプチドクリアリング剤 Pending JP2013505287A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0916749.5 2009-09-23
GBGB0916749.5A GB0916749D0 (en) 2009-09-23 2009-09-23 Peptide cleaning agents
PCT/GB2010/001796 WO2011036457A1 (en) 2009-09-23 2010-09-23 Peptide clearing agents

Publications (2)

Publication Number Publication Date
JP2013505287A true JP2013505287A (ja) 2013-02-14
JP2013505287A5 JP2013505287A5 (https=) 2013-11-14

Family

ID=41327500

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012530331A Pending JP2013505287A (ja) 2009-09-23 2010-09-23 ペプチドクリアリング剤

Country Status (16)

Country Link
US (1) US8846861B2 (https=)
EP (1) EP2470216A1 (https=)
JP (1) JP2013505287A (https=)
KR (1) KR20120084298A (https=)
CN (1) CN102665768B (https=)
AU (1) AU2010299643B2 (https=)
BR (1) BR112012006389A2 (https=)
CA (1) CA2774081A1 (https=)
GB (1) GB0916749D0 (https=)
IL (1) IL218713A0 (https=)
IN (1) IN2012DN02241A (https=)
MX (1) MX2012003565A (https=)
NZ (1) NZ598802A (https=)
SG (1) SG179015A1 (https=)
WO (1) WO2011036457A1 (https=)
ZA (1) ZA201201527B (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2435510A (en) 2006-02-23 2007-08-29 Mologic Ltd Enzyme detection product and methods
WO2012021512A2 (en) 2010-08-10 2012-02-16 Ecole Polytechnique Federale De Lausanne Erythrocyte-binding therapeutics
US9517257B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US9850296B2 (en) 2010-08-10 2017-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US10953101B2 (en) 2014-02-21 2021-03-23 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US10946079B2 (en) 2014-02-21 2021-03-16 Ecole Polytechnique Federale De Lausanne Glycotargeting therapeutics
US10046056B2 (en) 2014-02-21 2018-08-14 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
KR102717969B1 (ko) 2014-02-21 2024-10-15 에꼴 뽈리떼끄닉 뻬데랄 드 로잔느 (으뻬에프엘) 글리코타겟팅 치료제
US11253579B2 (en) 2017-06-16 2022-02-22 The University Of Chicago Compositions and methods for inducing immune tolerance
EA202092723A1 (ru) 2018-05-09 2021-04-09 Зе Юниверсити Оф Чикаго Композиции и способы, касающиеся иммунной толерантности
IL294515A (en) 2020-01-31 2022-09-01 Avilar Therapeutics Inc Compounds bind asgpr to degrade extracellular proteins
WO2022235699A2 (en) 2021-05-03 2022-11-10 Avilar Therapeutics, Inc. Potent asgpr-binding compounds for the degradation of immunoglobulins and other proteins

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000502071A (ja) * 1995-12-06 2000-02-22 エンザクタ アール アンド ディ リミテッド 薬物療法
JP2001505220A (ja) * 1996-11-30 2001-04-17 エンザクタ、アール、アンド、ディー、リミテッド 腫瘍の治療法
JP2001510453A (ja) * 1996-10-31 2001-07-31 ノヴァロン ファーマスーチカル コーポレイション 相補的組み合わせライブラリーを使用する薬剤の同定
JP2004535560A (ja) * 2001-04-20 2004-11-25 ザ ユニヴァーシティ オブ ジョージア リサーチファウンデーション， インク． 活性部位不活性化因子
JP2005503768A (ja) * 2001-04-03 2005-02-10 イムノメディクス， インコーポレイテッド 二重特異性抗体とともに使用される新規なペプチド型薬剤の製造および使用
JP2006506325A (ja) * 2002-05-17 2006-02-23 イミューノメディクス、インコーポレイテッド 二重特異性抗体ならびにキャリアペプチドと活性薬剤を含むハプテン構築物を用いる薬物プレターゲッティング
JP2009509535A (ja) * 2005-09-27 2009-03-12 アムニクス， インコーポレイテッド タンパク様薬剤およびその使用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6075010A (en) 1992-06-09 2000-06-13 Neorx Corporation Small molecular weight ligand-hexose containing clearing agents
US4859449A (en) 1987-09-14 1989-08-22 Center For Molecular Medicine And Immunology Modified antibodies for enhanced hepatocyte clearance
US20030068322A1 (en) 1988-04-18 2003-04-10 Immunomedics, Inc. Methods of antibody-directed enzyme-prodrug therapy
EP0538268A4 (en) 1990-05-11 1993-05-12 The University Of Connecticut Targeted protection from cytotoxins
GB9324807D0 (en) 1993-12-03 1994-01-19 Cancer Res Campaign Tech Tumour antibody
US6172045B1 (en) * 1994-12-07 2001-01-09 Neorx Corporation Cluster clearing agents
EP0837696B1 (en) 1995-06-07 2010-02-24 Immunomedics, Inc. Improved delivery of diagnostic and therapeutic agents to a target site
US6465612B1 (en) * 1998-09-23 2002-10-15 The Regents Of The University Of California Synthetic peptides, conjugation reagents and methods
ATE514711T1 (de) 2007-10-16 2011-07-15 Toscana Biomarkers S R L Galactosylierte peptide, deren zubereitung und verwendung zur diagnose von autoimmunerkrankungen

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000502071A (ja) * 1995-12-06 2000-02-22 エンザクタ アール アンド ディ リミテッド 薬物療法
JP2001510453A (ja) * 1996-10-31 2001-07-31 ノヴァロン ファーマスーチカル コーポレイション 相補的組み合わせライブラリーを使用する薬剤の同定
JP2001505220A (ja) * 1996-11-30 2001-04-17 エンザクタ、アール、アンド、ディー、リミテッド 腫瘍の治療法
JP2005503768A (ja) * 2001-04-03 2005-02-10 イムノメディクス， インコーポレイテッド 二重特異性抗体とともに使用される新規なペプチド型薬剤の製造および使用
JP2004535560A (ja) * 2001-04-20 2004-11-25 ザ ユニヴァーシティ オブ ジョージア リサーチファウンデーション， インク． 活性部位不活性化因子
JP2006506325A (ja) * 2002-05-17 2006-02-23 イミューノメディクス、インコーポレイテッド 二重特異性抗体ならびにキャリアペプチドと活性薬剤を含むハプテン構築物を用いる薬物プレターゲッティング
JP2009509535A (ja) * 2005-09-27 2009-03-12 アムニクス， インコーポレイテッド タンパク様薬剤およびその使用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BAGSHAWE, K.D.: ""TARGETING: THE ADEPT STORY SO FAR"", CURRENT DRUG TARGETS, vol. 10, no. 2, JPN5012016876, 1 February 2009 (2009-02-01), US, pages 152 - 157, XP008130166, ISSN: 0002973167 *
SHARMA, S.K. ET AL.: ""Galactosylated antibodies and antibody-enzyme conjugates in antibody-directed enzyme prodrug therap", CANCER, vol. Vol.73, No.3 Suppl., JPN6014054379, 1 February 1994 (1994-02-01), pages 1114 - 1120, ISSN: 0002973166 *

Also Published As

Publication number Publication date
CN102665768A (zh) 2012-09-12
AU2010299643A1 (en) 2012-03-22
SG179015A1 (en) 2012-04-27
IN2012DN02241A (https=) 2015-08-21
AU2010299643B2 (en) 2014-06-26
US20130053543A1 (en) 2013-02-28
WO2011036457A1 (en) 2011-03-31
BR112012006389A2 (pt) 2016-11-22
MX2012003565A (es) 2012-08-03
EP2470216A1 (en) 2012-07-04
GB0916749D0 (en) 2009-11-04
CA2774081A1 (en) 2011-03-31
CN102665768B (zh) 2015-01-21
US8846861B2 (en) 2014-09-30
NZ598802A (en) 2013-10-25
KR20120084298A (ko) 2012-07-27
IL218713A0 (en) 2012-05-31
ZA201201527B (en) 2013-05-29

Similar Documents

Publication Publication Date Title
JP2013505287A (ja) ペプチドクリアリング剤
JP7116217B2 (ja) Ｍｔ１－ｍｍｐに特異的な二環性ペプチドリガンド
US12492224B2 (en) Bicyclic peptide ligands specific for PD-L1
JP7417432B2 (ja) 新規リンカー、その製造方法およびその応用
JP7291395B2 (ja) ＩｇＧ結合ペプチド、及び該ペプチドによる抗体の特異的修飾
JP6970090B2 (ja) Ｃ末端リジンで結合体化された免疫グロブリン
AU2010203353B2 (en) Modified antibody compositions, methods of making and using thereof
US20230270854A1 (en) Modified antibodies
JP2019523214A (ja) Ｍｔ１−ｍｍｐに対して特異的な二環式ペプチド−毒素コンジュゲート
JP5677454B2 (ja) 細胞内ターゲット結合用二座ペプチドバインダー
KR20210143127A (ko) 신규 뉴클레오린-결합 펩타이드 및 이의 용도
WO2022080385A1 (ja) ペプチド、およびペプチドを用いる抗体の修飾
Ucar et al. A new radio-theranostic agent candidate: Synthesis and analysis of (ADH-1) c-EDTA conjugate
WO2026005714A1 (en) Engineer next-generation antibody-drug conjugates using orthogonal bioconjugation methods
EP4333902A1 (en) Methods and compositions thereof for site-specific labeling of human igg by proximity-based sortase-mediated ligation
JPS6185327A (ja) 発癌遺伝子生成物に対する抗体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130920

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130920

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150106

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150331

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150915